Summary
The α-glucosidase inhibitor BAY m 1099, a deoxynojirimycin derivative, was studied
in sulfonylurea-treated type II diabetic patients using a placebo-controlled double-blind
crossover design.
Given in two daily doses the inhibitor smoothened the blood glucose profile by lowering
significantly post-prandial blood glucose peaks.
Fasting and daily mean blood glucose levels measured as the area under the blood glucose
curves were however not influenced significantly. This might be due to the short duration
of the treatment periods or the low dosage of the drug.
Abdominal side effects were negligible.
The α-glucosidase inhibitor BAY m 1099 might become a useful therapeutic tool in addition
to sulfonylurea treatment in type II diabetes.
Key-Words
Type II Diabetes
-
Intestinal Carbohydrate Resorption
-
Glucosidase Inhibitors
-
Deoxynojirimycin Derivative
